慢性腎疾患と多発性骨髄腫の患者におけるレナリドミド誘発性耐火性低カルセミア:症例報告と文献レビュー
Denise Maria do Nascimento Costa, Italo Rafael Correia Alves, Luiz Fernando Menezes Soares de Azevedo
Clinical nephrology
|September 1, 2025
まとめ
レナリドミドは慢性腎臓病 (CKD) の患者で重度の低カルシウム症を引き起こす可能性があります. レナリドミドの治療を中止すると,多発性骨髄腫患者の低カルシウム症候群は成功しました.
科学分野:
- 腎臓科
- 血液学
- 薬理学について
背景:
- レナリドミドは,多発性骨髄腫に一般的に使用される免疫調節薬です.
- 低カルセミアはレナリドミド治療の希少だが重大な副作用である.
- 慢性腎疾患 (CKD) は,レナリドミドによる低カルシウム血症のリスクを増加させる可能性があります.
研究 の 目的:
- レナリドミドで治療された多発性骨髄腫と慢性腎臓病の患者の症状性耐性低カルシウム症候群を報告する
- レナリドミドと重度の低カルシウム血症の関連性を強調する.
- 臨床医に この潜在的副作用を 警告するためです
主な方法:
- ステージG4-5のCKDと多発性骨髄腫の女性患者の症例報告
- レナリドミド治療前と治療中の血清カルシウム,リン,副甲状腺ホルモンのモニタリング.
- 経口補給と腎置換治療に対する反応の評価
- レナリドミドの投与中止後の低カルセミアの評価
主要な成果:
- レナリドミド治療の1ヶ月後,患者は症状のある低カルセミア (血清Ca 6. 37. 6 mg/ dL) を発症した.
- 高用量カルシトリオールとカルシウム炭酸を含む標準治療は効果的ではなかった.
- 腎臓置換療法は 低カルシウム血症を修正できなかった.
- レナリドミドの投与を中止してから1ヶ月以内に,低カルシウム症は治りました.
結論:
- レナリドミド治療は,特に慢性腎臓病の患者では,耐性低カルシウム症を引き起こす可能性があります.
- レナリドミドの投与を中止することは,この副作用の管理に不可欠です.
- ヘマトロジストや腎臓科医は,レナリドミドを服用している患者,特に腎臓機能障害のある患者では,低カルシウム症候群に注意する必要があります.
関連する概念動画
01:24Chronic Kidney Disease II: Clinical Manifestations
85
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
85
01:11Renal Failure: Dose Adjustments
152
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
152
01:18Chronic Kidney Disease IV: Nursing Management
54
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
54
01:28Chronic Kidney Disease III: Interprofessional Care
77
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
77
01:25Chronic Kidney Disease I: Introduction
65
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
65
01:17Antiepileptic Drugs: Calcium Channel Blockers
608
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
608